AU2021267217A1 - Stable cyclosporine ophthalmic formulation and manufacturing process thereof - Google Patents
Stable cyclosporine ophthalmic formulation and manufacturing process thereof Download PDFInfo
- Publication number
- AU2021267217A1 AU2021267217A1 AU2021267217A AU2021267217A AU2021267217A1 AU 2021267217 A1 AU2021267217 A1 AU 2021267217A1 AU 2021267217 A AU2021267217 A AU 2021267217A AU 2021267217 A AU2021267217 A AU 2021267217A AU 2021267217 A1 AU2021267217 A1 AU 2021267217A1
- Authority
- AU
- Australia
- Prior art keywords
- cyclosporine
- temperature
- mixture
- stable
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202121037917 | 2021-08-20 | ||
| IN202121037917 | 2021-08-20 | ||
| PCT/IB2021/059176 WO2021224901A2 (en) | 2021-08-20 | 2021-10-06 | Stable cyclosporine ophthalmic formulation and manufacturing process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021267217A1 true AU2021267217A1 (en) | 2024-02-29 |
Family
ID=78468801
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021267217A Pending AU2021267217A1 (en) | 2021-08-20 | 2021-10-06 | Stable cyclosporine ophthalmic formulation and manufacturing process thereof |
| AU2022330409A Pending AU2022330409A1 (en) | 2021-08-20 | 2022-08-22 | Stable cyclosporine ophthalmic formulation and manufacturing process thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022330409A Pending AU2022330409A1 (en) | 2021-08-20 | 2022-08-22 | Stable cyclosporine ophthalmic formulation and manufacturing process thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240342086A1 (https=) |
| EP (2) | EP4387589A4 (https=) |
| JP (2) | JP2024530244A (https=) |
| CN (2) | CN117957011A (https=) |
| AU (2) | AU2021267217A1 (https=) |
| IL (2) | IL310823A (https=) |
| MX (2) | MX2024002234A (https=) |
| WO (2) | WO2021224901A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4719350A1 (en) * | 2023-05-29 | 2026-04-08 | Sun Pharmaceutical Industries Limited | Stable cyclosporine ophthalmic formulation and manufacturing process thereof |
| WO2025163677A1 (en) * | 2024-01-31 | 2025-08-07 | Registrar, Panjab University, Chandigarh | Nanomicellar composition for high permeation and extended-release drug delivery system |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2836946C (en) * | 2011-05-27 | 2017-08-01 | Allergan, Inc. | A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof |
| PL2887923T3 (pl) * | 2012-08-24 | 2023-08-14 | Sun Pharmaceutical Industries Limited | Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu |
| US20200237859A1 (en) * | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
| EP3373976B1 (en) * | 2015-11-10 | 2024-01-03 | Sun Pharmaceutical Industries Limited | Topical formulations and uses thereof |
| US10918694B2 (en) * | 2016-02-29 | 2021-02-16 | Sun Pharma Global Fze | Topical cyclosporine-containing formulations and uses thereof |
-
2021
- 2021-10-06 WO PCT/IB2021/059176 patent/WO2021224901A2/en not_active Ceased
- 2021-10-06 JP JP2024509421A patent/JP2024530244A/ja active Pending
- 2021-10-06 US US18/683,943 patent/US20240342086A1/en active Pending
- 2021-10-06 CN CN202180102266.5A patent/CN117957011A/zh active Pending
- 2021-10-06 AU AU2021267217A patent/AU2021267217A1/en active Pending
- 2021-10-06 EP EP21800075.0A patent/EP4387589A4/en active Pending
- 2021-10-06 IL IL310823A patent/IL310823A/en unknown
- 2021-10-06 MX MX2024002234A patent/MX2024002234A/es unknown
-
2022
- 2022-08-22 US US18/683,932 patent/US20240423912A1/en active Pending
- 2022-08-22 CN CN202280007116.0A patent/CN116528838A/zh active Pending
- 2022-08-22 IL IL310887A patent/IL310887A/en unknown
- 2022-08-22 JP JP2024509422A patent/JP2024530245A/ja active Pending
- 2022-08-22 AU AU2022330409A patent/AU2022330409A1/en active Pending
- 2022-08-22 EP EP22768958.5A patent/EP4387591A1/en active Pending
- 2022-08-22 WO PCT/IB2022/057851 patent/WO2023021492A1/en not_active Ceased
- 2022-08-22 MX MX2024002235A patent/MX2024002235A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4387589A2 (en) | 2024-06-26 |
| EP4387589A4 (en) | 2025-09-03 |
| AU2022330409A1 (en) | 2024-02-29 |
| US20240423912A1 (en) | 2024-12-26 |
| IL310887A (en) | 2024-04-01 |
| EP4387591A1 (en) | 2024-06-26 |
| MX2024002235A (es) | 2024-06-11 |
| JP2024530245A (ja) | 2024-08-16 |
| MX2024002234A (es) | 2024-04-17 |
| CN117957011A (zh) | 2024-04-30 |
| IL310823A (en) | 2024-04-01 |
| WO2021224901A3 (en) | 2021-12-30 |
| US20240342086A1 (en) | 2024-10-17 |
| JP2024530244A (ja) | 2024-08-16 |
| WO2023021492A1 (en) | 2023-02-23 |
| CN116528838A (zh) | 2023-08-01 |
| WO2021224901A2 (en) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7547411B2 (ja) | 局所用シクロスポリン含有製剤およびその使用 | |
| WO2018036522A1 (zh) | 羊毛甾醇类化合物眼用制剂 | |
| US20210177933A1 (en) | Method of treating ophthalmic conditions | |
| US20240423912A1 (en) | Stable cyclosporine ophthalmic formulation and manufacturing process thereof | |
| HK40114670A (en) | Topical cyclosporine-containing formulations and uses thereof | |
| EP4719350A1 (en) | Stable cyclosporine ophthalmic formulation and manufacturing process thereof | |
| HK40002770B (en) | Topical cyclosporine-containing formulations and uses thereof | |
| HK40002770A (en) | Topical cyclosporine-containing formulations and uses thereof |